SurModics Names Jan Webster Vice President of Human Resources
EDEN PRAIRIE, Minn., Jan 09, 2006 (BUSINESS WIRE) -- SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and drug delivery technologies to the healthcare industry, announced today that Jan Marie Webster has joined the company as Vice President of Human Resources. Ms. Webster has over 20 years experience in the healthcare industry, most recently as Director of Human Resources for the Cardiac Surgery division of St. Jude Medical, Inc.
"We are delighted to welcome Jan to our senior management team," said Bruce Barclay, President and Chief Executive Officer. "Her extensive background in the medical device industry and significant human resources experience, including noteworthy leadership development skills, will benefit SurModics for years to come."
"I am very excited to join the SurModics team," commented Ms. Webster. "SurModics has top-notch talent, cutting edge technologies and is focused on very attractive target markets. I believe that my extensive industry experience and demonstrated human resources capabilities will facilitate the expansion and development of SurModics' employee base and management team, and will provide great benefit to this growing business."
Webster graduated cum laude from Minnesota State University, Mankato with a bachelor's degree in business administration. She earned her M.A. in human resources and industrial relations from the University of Minnesota.
About SurModics, Inc.
SurModics, Inc. is a leading provider of surface modification technologies, in the areas of biocompatibility, site-specific drug delivery, biological cell encapsulation, and medical diagnostics. SurModics partners with the world's foremost medical device, pharmaceutical and life science companies to bring innovation together for better patient outcomes. A significant portion of SurModics' revenue is generated by royalties from the sale of commercial products resulting from its corporate relationships. Recent collaborative efforts include the implementation of the SurModics' Bravo(TM) drug delivery polymer matrix as a key component in the first-to-market drug-eluting coronary stent. SurModics is headquartered in Eden Prairie, MN and more information about the company can be found at www.surmodics.com. The content of SurModics' web site is not part of this release or part of any filings the company makes with the SEC.
Forward Looking Statements
Certain statements contained in this press release may be deemed to be forward-looking statements under federal securities laws, and SurModics intends that such forward looking statements be subject to the safe harbor created thereby. Factors that may cause actual results to differ from the forward-looking statements include those described in the "Risk Factors" and other sections of SurModics' filings with the Securities and Exchange Commission. SurModics does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE: SurModics, Inc.
SurModics, Inc. Phil Ankeny, 952-829-2700